The stock may react negatively to widening losses and Nasdaq compliance risks despite the licensing deal. Monitor the April 7 hearing outcome and future revenue trends under the new licensing structure with Future Pak.
Price Chart
Executive Summary
Jaguar Health reported 2025 financial results showing a 5% sequential increase in Q4 2025 revenue to $3.2M, but an 8% decline year-over-year. The company announced a $16M non-dilutive licensing deal with Future Pak and faces a Nasdaq listing compliance issue under appeal. Net loss widened to $53.6M from $38.5M in 2024.
Key Financial Metrics
Key Facts
- Q4 2025 net revenue: $3.2M, up 5% QoQ but down 8% YoY from $3.5M
- 2025 total net revenue: $11.5M, down 1.5% from $11.7M in 2024
- Net loss attributable to common shareholders: $53.6M in 2025 vs $38.5M in 2024
- Received $16M upfront payment from Future Pak licensing deal in January 2025
- Nasdaq issued non-compliance determination on March 5, 2026 for minimum bid price, hearing scheduled for April 7, 2026
- Impairment loss of $0.8M on intangible assets due to delays in IBS and PEDS programs
Financial Impact
Revenue declined 1.5% year-over-year to $11.5M while net loss increased by $15.1M to $53.6M, with a $0.8M impairment charge
Risk Factors
- Nasdaq delisting risk pending hearing decision
- Continued revenue decline and increasing losses
- Dependence on future milestone payments from licensing deal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-144604 |
| Document: d111491d8k.htm | 0001193125-26-144604 |
| Document: 0001193125-26-144604-index-headers.html | 0001193125-26-144604 |
| Document: 0001193125-26-144604-index.html | 0001193125-26-144604 |
| Document: 0001193125-26-144604.txt | 0001193125-26-144604 |
| 8-K Data (Synthetic) | 0001193125-26-144604 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers